Kezar Life Sciences, Inc. (NASDAQ:KZR) Receives $6.00 Consensus Target Price from Brokerages

Kezar Life Sciences, Inc. (NASDAQ:KZR) has been assigned an average recommendation of “Reduce” from the six ratings firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $6.00.

KZR has been the topic of a number of research analyst reports. William Blair reaffirmed a “market perform” rating on shares of Kezar Life Sciences in a report on Friday, October 17th. Wells Fargo & Company set a $5.00 target price on Kezar Life Sciences and gave the stock an “equal weight” rating in a research report on Friday, October 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Kezar Life Sciences in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Kezar Life Sciences to a “hold” rating in a research report on Saturday, November 22nd. Finally, TD Cowen cut shares of Kezar Life Sciences from a “strong-buy” rating to a “strong sell” rating in a report on Friday, October 17th.

Institutional Investors Weigh In On Kezar Life Sciences

Institutional investors have recently added to or reduced their stakes in the business. Landscape Capital Management L.L.C. purchased a new stake in Kezar Life Sciences in the 3rd quarter worth $51,000. Woodline Partners LP purchased a new position in shares of Kezar Life Sciences during the first quarter valued at $125,000. Peapod Lane Capital LLC raised its stake in Kezar Life Sciences by 9.3% in the third quarter. Peapod Lane Capital LLC now owns 125,773 shares of the company’s stock worth $491,000 after buying an additional 10,650 shares in the last quarter. Stonepine Capital Management LLC lifted its position in shares of Kezar Life Sciences by 69.9% during the second quarter. Stonepine Capital Management LLC now owns 169,859 shares of the company’s stock valued at $778,000 after buying an additional 69,859 shares during the last quarter. Finally, BML Capital Management LLC boosted its position in shares of Kezar Life Sciences by 13.5% in the 3rd quarter. BML Capital Management LLC now owns 720,787 shares of the company’s stock worth $2,811,000 after purchasing an additional 85,604 shares in the last quarter. 67.90% of the stock is owned by hedge funds and other institutional investors.

Kezar Life Sciences Trading Up 0.5%

Shares of KZR opened at $6.28 on Friday. The stock’s 50-day moving average is $5.65 and its two-hundred day moving average is $4.69. The stock has a market cap of $45.97 million, a PE ratio of -0.74 and a beta of 0.50. Kezar Life Sciences has a 12 month low of $3.53 and a 12 month high of $7.05. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.07 and a quick ratio of 7.06.

Kezar Life Sciences (NASDAQ:KZR) last announced its earnings results on Wednesday, November 12th. The company reported ($1.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.81) by $0.28. Equities analysts forecast that Kezar Life Sciences will post -4.39 earnings per share for the current fiscal year.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.